Juno Therapeutics bring in new executive vice president
pharmafile | January 27, 2017 | Appointment | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | Genentech, Roche, juno therapeutics
Juno Therapeutics has hired Corsee D. Sanders as its executive vice president and head of development operations. She will step into the role immediately, joining Juno after nearly five years working at Roche as global head of Roche pharmaceuticals clinical operations and external collaboration.
Prior to working in this role, she was held several roles at Genentech for 17 years. In this role, Sanders oversaw the development and submission of Rituxan, Herceptin and Avastin.
“I am delighted to join Juno at an exciting time in the company’s history, and am looking forward to being a part of developing innovative new medicines for patients with difficult diseases,” said Dr. Sanders. “I have been privileged to be a part of bringing highly successful products to market at other companies and am excited to bring that experience to Seattle and Juno.”
“Corsee is a dynamic leader, and a terrific addition to our executive team,” said Hans Bishop, president and CEO of Juno. “Juno’s next phase of growth will benefit from her expertise in the data sciences, her experience leading complex development organizations, and her relentless focus on execution as a strategic advantage.”
Related Content

Roche receives CE Mark for blood test to help rule out Alzheimer’s
Roche has been granted CE Mark approval for its Elecsys pTau181 test, the first in …

Roche candidate shows early promise for treating haemophilia A
Roche has announced encouraging early results from its phase 1/2 trial of NXT007, an investigational …

Roche advances treatment for Parkinson’s disease
Swiss biopharma, Roche, has announced its decision to proceed with phase 3 trials of prasinezumab, …






